01 septiembre 2016

INTERNATIONAL JOURNAL OF CARDIOLOGY. Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents

Mineok Chang, MD1, Jung-Min Ahn, MD1, Nayoung Kim, BS, Pil Hyung Lee, MD, Jae-Hyung Roh, MD, Sung-Han Yoon, MD, Soo-Jin Kang, MD, Seung-Whan Lee, MD, Young-Hak Kim, MD, Cheol Whan Lee, MD, Seong-Wook Park, MD, Duk-Woo Park, MD, Seung-Jung Park, MD

Background: The clinical impact of completeness of revascularization on adverse cardiovascular events remains unclear among patients with multivessel coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI).

01 septiembre 2016

INTERNATIONAL JOURNAL OF CARDIOLOGY. Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012

Christian McNeely, MD1, Stephen Markwell, MA, Christina M. Vassileva, MD

Background: Since year 2000, reducing hospital readmissions has become a public health priority. In addition, there have been major changes in percutaneous coronary intervention (PCI) during this period.

01 octubre 2016

INTERNATIONAL JOURNAL OF CARDIOLOGY. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy

Steven Sra, MD, Mary K. Tan, MSc, Shamir R. Mehta, MD, MSc, Harold N. Fisher, MD, Jean-Pierre Déry, MD, Robert C. Welsh, MD, Mark J. Eisenberg, MD, MPH, Christopher B. Overgaard, MD, MSc, Barry F. Rose, MD, Anthony J. Della Siega, MD, Asim N. Cheema, MD, Brian Y.L. Wong, MD, Mark A. Henderson, MD, Sohrab Lutchmedial, MD, CM, Shahar Lavi, MD, Shaun G. Goodman, MD, MSc, Andrew T. Yan, MD, for the Canadian Observational AntiPlatelet sTudy (COAPT) Investigators

Background: Since the introduction of newer, more potent P2Y12 receptor inhibitors (P2Y12ris), practice patterns and associated clinical outcomes in patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI) and also requiring oral anticoagulation (OAC) have not been fully characterized.

01 agosto 2016

JACC. Cerebral Embolism During Transcatheter Aortic Valve Replacement. The BRAVO-3 MRI Study

Eric Van Belle, MD, PhDa; Christian Hengstenberg, MDb,c; Thierry Lefevre, MDd; Christian Kupatt, MDe; Nicolas Debry, MDa; Oliver Husser, MD, PhDb; François Pontana, MD, PhDf; Grégory Kuchcinski, MDf; Efthymios N. Deliargyris, MDg; Roxana Mehran, MDh; Debra Bernstein, PhDg; Prodromos Anthopoulos, MDi; George D. Dangas, MD, PhDh

Background: Cerebral embolization is a frequent complication after transcatheter aortic valve replacement (TAVR). We hypothesized that cerebral embolization may be reduced by anticoagulation with bivalirudin during TAVR.

01 agosto 2016

JACC. Cardiovascular Magnetic Resonance to Evaluate Aortic Regurgitation After Transcatheter Aortic Valve Replacement

Henrique B. Ribeiro, MD, PhDa; Stefan Orwat, MDb; Salim S. Hayek, MDc; Éric Larose, MDa; Vasilis Babaliaros, MDc; Abdellaziz Dahou, MDa; Florent Le Ven, MDa; Sergio Pasian, MDa; Rishi Puri, MBBS, PhDa; Omar Abdul-Jawad Altisent, MDa; Francisco Campelo-Parada, MDa; Marie-Annick Clavel, PhDa; Philippe Pibarot, DVM, PhDa; Stamatios Lerakis, MDc; Helmut Baumgartner, MDb; Josep Rodés-Cabau, MDa

Background: Residual aortic regurgitation (AR) following transcatheter aortic valve replacement (TAVR) is associated with greater mortality; yet, determining AR severity post-TAVR using Doppler echocardiography remains challenging. Cardiovascular magnetic resonance (CMR) is purported as a more accurate means of quantifying AR; however, no data exist regarding the prognostic value of AR as assessed by CMR post-TAVR.

01 septiembre 2016

JACC. Transcatheter Aortic Valve Replacement With Early- and New-Generation Devices in Bicuspid Aortic Valve Stenosis

Sung-Han Yoon, MDa; Thierry Lefèvre, MDb; Jung-Ming Ahn, MDa; Gidon Y. Perlman, MDc; Danny Dvir, MDc; Azeem Latib, MDd; Marco Barbanti, MDe; Florian Deuschl, MDf; Ole De Backer, MDg; Philipp Blanke, MDc; Thomas Modine, MDh; Gregor Pache, MDi; Franz-Josef Neumann, MDj; Philipp Ruile, MDj; Takahide Arai, MDb; Yohei Ohno, MDe; Hidehiro Kaneko, MDk; Edgar Tay, MDl; Niklas Schofer, MDf; Erik W. Holy, MDm; Ngai H.V. Luk, MDg; Gerald Yong, MDn; Qingsheng Lu, MDo; William K.F. Kong, MDl,p; Jimmy Hon, MDl; Hsien-Li Kao, MDq; Michael Lee, MDr; Wei-Hsian Yin, MDs; Duk-Woo Park, MDa; Soo-Jin Kang, MDa; Seung-Whan Lee, MDa; Young-Hak Kim, MDa; Cheol Whan Lee, MDa; Seong-Wook Park, MDa; Hyo-Soo Kim, MDt; Christian Butter, MDk; Omar K. Khalique, MDu; Ulrich Schaefer, MDf; Fabian Nietlispach, MDm; Susheel K. Kodali, MDu; Martin B. Leon, MDu; Jian Ye, MDc; Bernard Chevalier, MDb; Jonathon Leipsic, MDc; Victoria Delgado, MDq; Jeroen J. Bax, MDq; Corrado Tamburino, MDe; Antonio Colombo, MDd; Lars Søndergaard, MDg; John G. Webb, MDc; Seung-Jung Park, MDa

Background: Few studies have evaluated the clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve stenosis (AS). Particularly, limited data exist comparing the results of TAVR with new-generation devices versus early-generation devices.

01 septiembre 2016

JACC. Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease

Rafael Cavalcante, MD, PhDa,b; Yohei Sotomi, MDc; Cheol W. Lee, MDd; Jung-Min Ahn, MDd; Vasim Farooq, MD, PhDe; Hiroki Tateishi, MD, PhDa; Erhan Tenekecioglu, MDa; Yaping Zeng, MD, PhDa; Pannipa Suwannasom, MDc; Carlos Collet, MDc; Felipe N. Albuquerque, MDa; Yoshinobu Onuma, MD, PhDa; Seung-Jung Park, MD, PhDd; Patrick W. Serruys, MD, PhDf

Background: Currently available randomized data on the comparison between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) for the treatment of unprotected left main coronary disease (LMD) lacks statistical power due to low numbers of patients enrolled.

01 agosto 2016

JACC. Outcomes of Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Nadia R. Sutton, MD, MPHa; Milan Seth, MSa; Cyril Ruwende, MD, PhDb; Hitinder S. Gurm, MBBSa,c

Background: Atrial fibrillation (AF) is increasing in prevalence, and patients with a history of AF commonly undergo percutaneous coronary intervention (PCI). There is a paucity of contemporary data on the association between AF and clinical outcomes after PCI.

01 agosto 2016

JACC. Coronary Physiology During Exercise and Vasodilation in the Healthy Heart and in Severe Aortic Stenosis

Matthew Lumley, BSca; Rupert Williams, BSca; Kaleab N. Asrress, PhDa; Satpal Arri, BSca; Natalia Briceno, BSca; Howard Ellis, BSca; Ronak Rajani, MDb; Maria Siebes, PhDc; Jan J. Piek, PhD, MDd; Brian Clapp, PhDb; Simon R. Redwood, MDa,b; Michael S. Marber, PhDa; John B. Chambers, MDb; Divaka Perera, MDa,b

Background: Severe aortic stenosis (AS) can manifest as exertional angina even in the presence of unobstructed coronary arteries.

01 agosto 2016

JACC. Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction

Sunil V. Rao, MDa; Uwe Zeymer, MDb; Pamela S. Douglas, MDa; Hussein Al-Khalidi, PhDa; Jennifer A. White, MSa; Jingyu Liu, PhDc; Howard Levy, MD, PhDc; Victor Guetta, MDd; C. Michael Gibson, MDe; Jean-Francois Tanguay, MDf; Paul Vermeersch, MDg; Jérôme Roncalli, MD, PhDh; Jaroslaw D. Kasprzak, MDi; Timothy D. Henry, MDj; Norbert Frey, MDk; Oscar Kracoff, MDl; Jay H. Traverse, MDm; Derek P. Chew, MBBSn; Jose Lopez-Sendon, MDo; Reinilde Heyrman, MDc; Mitchell W. Krucoff, MDa

Background: Bioabsorbable cardiac matrix (BCM) is a novel device that attenuates adverse left ventricular (LV) remodeling after large myocardial infarctions in experimental models.

01 agosto 2016

JACC. Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Vincent Auffret, MD, MSca,b; Ander Regueiro, MDa; María Del Trigo, MDa; Omar Abdul-Jawad Altisent, MDa; Francisco Campelo-Parada, MDa; Olivier Chiche, MDa; Rishi Puri, MBBS, PhDa; Josep Rodés-Cabau, MDa

Background: Identifying transcatheter aortic valve replacement (TAVR) patients at high risk for cerebrovascular events (CVE) is of major clinical relevance. However, predictors have varied across studies.

01 septiembre 2016

JACC. Association of Systolic Blood Pressure Variability With Mortality, Coronary Heart Disease, Stroke, and Renal Disease

Elvira O. Gosmanova, MDa,b; Margit K. Mikkelsen, BSc; Miklos Z. Molnar, MD, PhDd; Jun L. Lu, MDd; Lenar T. Yessayan, MD, MSe; Kamyar Kalantar-Zadeh, MD, MPH, PhDf; Csaba P. Kovesdy, MDd,g

Background: Intraindividual blood pressure (BP) fluctuates dynamically over time. Previous studies suggested an adverse link between greater visit-to-visit variability in systolic blood pressure (SBP) and various outcomes. However, these studies have significant limitations, such as a small size, inclusion of selected populations, and restricted outcomes.

01 septiembre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Major Predictors of Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Coronary Bifurcation Lesions With 2-Stent Strategy. Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts

Pil Sang Song, MDa; Young Bin Song, MD, PhDb; Joo Myung Lee, MD, MPHb; Joo-Yong Hahn, MD, PhDb; Seung-Hyuk Choi, MD, PhDb; Jin-Ho Choi, MD, PhDb; Sang Hoon Lee, MD, PhDb; Kyung Woo Park, MD, PhDc; Hyo-Soo Kim, MD, PhDc; Yangsoo Jang, MD, PhDd; Ki Bae Seung, MD, PhDe; Ju Hyeon Oh, MD, PhDf; Hyeon-Cheol Gwon, MD, PhDb

Objectives: This study investigated the long-term outcomes and predictors of target vessel failure (a composite of cardiac death, myocardial infarction, stent thrombosis, or target vessel revascularization) in patients with bifurcation lesion treated by percutaneous coronary intervention (PCI) utilizing the 2-stent strategy with a drug-eluting stent (DES).

01 septiembre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration

Gennaro Giustino, MDa; Ioannis Mastoris, MDa; Usman Baber, MD, MSca; Samantha Sartori, PhDa; Gregg W. Stone, MDb; Martin B. Leon, MDb; Patrick W. Serruys, MD, PhDc; Adnan Kastrati, MDd; Stephan Windecker, MD, PhDe; Marco Valgimigli, MD, PhDe; George D. Dangas, MD, PhDa; Clemens Von Birgelen, MDf; Pieter C. Smits, MDg; David Kandzari, MDh; Soren Galatius, MDi; William Wijns, MDj; P. Gabriel Steg, MD, PhDk; Giulio G. Stefanini, MD, PhDl; Melissa Aquino, MSca; Marie-Claude Morice, MDm; Edoardo Camenzind, MDn; Giora Weisz, MDo,p; Raban V. Jeger, MDq; Takeshi Kimura, MDr; Ghada W. Mikhail, MDs; Dipti Itchhaporia, MDt; Laxmi Mehta, MDu; Rebecca Ortega, MDv; Hyo-Soo Kim, MDw; Alaide Chieffo, MDx; Roxana Mehran, MDa

Objectives: The aim of this study was to investigate the clinical correlates and prognostic impact of coronary artery calcification (CAC) in women undergoing percutaneous coronary intervention with drug-eluting stents (DES).

01 septiembre 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. The CHAMPION PHOENIX Trial

Jérémie Abtan, MDa; P. Gabriel Steg, MDa,b; Gregg W. Stone, MDc; Kenneth W. Mahaffey, MDd; C. Michael Gibson, MDe; Christian W. Hamm, MDf; Matthew J. Price, MDg; Freddy Abnousi, MD, MBA, MScg; Jayne Prats, PhDh; Efthymios N. Deliargyris, MDh; Harvey D. White, DSci; Robert A. Harrington, MDd; Deepak L. Bhatt, MD, MPHj

Objectives: The purpose of this study was to examine the safety and efficacy of cangrelor in patients with stable angina (SA) or acute coronary syndrome (ACS).